Domestic pharmaceutical companies are increasingly looking at biosimilars to offset the declining profit margin from generic markets in developed countries, industry experts said. Biosimilars are generic versions of biotech drugs. Ranbaxy Laboratories recently raised its stake in biosimilar product company Zenotech Laboratories to 27.35 per cent. Ranbaxy has also made an open offer to buy 20 per cent more in Zenotech at Rs 160 a share.
